Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 27Active not recruiting 7Recruiting 6Unknown 3Terminated 3Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Lymphoma 2Immunoglobulin Light-chain Amyloidosis 2Triple Negative Breast Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms 1Neoplasm, Residual 1Malignant Plasma Cell Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia 1Hematologic Diseases 1Esophageal Stenosis 1Esophageal Neoplasms 1Corneal Diseases 1Breast Cancer Patients Treated With T-DXd 1Brain Neoplasms 1Blood Protein Disorders 1Ann Arbor Stage II Mantle Cell Lymphoma 1Amyloidosis 1

Interventions

Dexamethasone 2daratumumab 1belantamab mafodotin 1Cyclophosphamide 1Bortezomib 14-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Immunoglobulin Light-chain Amyloidosis × Dexamethasone × Clear all
NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Peking University People's Hospital

Phase 2 Not yet recruiting
39 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡